Lead: State-level racial and ethnic disparities in buprenorphine treatment duration in the United States

Lead: State-level racial and ethnic disparities in buprenorphine treatment duration in the United States

In this episode of 'This Week in Addiction Medicine', the American Society of Addiction Medicine dives into the critical issue of racial and ethnic disparities in buprenorphine treatment duration across the United States. The episode highlights a study that analysed over nine million buprenorphine prescriptions from 2011 to 2020, revealing stark differences in treatment durations among various racial and ethnic groups at the state level.

Particularly, 21 states showed longer treatment durations for White individuals, with eight states displaying similar trends for treatments lasting 180 days or more. This discussion is vital for understanding and addressing systemic inequities in addiction treatment. The episode also explores several other significant studies, including the impact of buprenorphine during pregnancy, interventions to reduce drug-related harms among incarcerated individuals, and the effects of household composition on substance use among young adults.

The hosts provide a comprehensive overview of these findings, offering valuable insights for healthcare providers, policymakers, and anyone interested in addiction medicine. Tune in to gain a deeper understanding of these pressing issues and their implications for improving addiction treatment and outcomes.